ANTI-Δ42PD1
ANTIBODY PLATFORM
PIPELINE
OUR
TEAM
Dr. Percy CHENG
MH
(Co-Founder)
Executive Director
Chairman of the Board
Dr. Xia JIN
(Co-Founder)
Executive Director
Chief Executive Officer
Mr. Peter TANG
(Co-Founder)
Director
Mr. Chibo TANG
Director
Dr. Che Hung LEONG, Edward
GBM, GBS, OBE, JP
Chairman of Advisory Board
Dr. Wing Man KO
GBS, JP
Advisory Board Member
Dr. Da I HO, David
Advisory Board Member
Prof. Zhiwei CHEN
(Co-Founder)
Advisory Board Member
and Principal Scientific Advisor
Mr. Tom LAU
(Co-Founder)
Director of Corporate Finance
Mr. Mark Lo
Chief Financial Officer
Dr. Michael WONG
Research and Development Director
Dr. Pele CHONG
Strategic Development Director
Dr. Sing Fai WAI
Chief Technology Officer
Ms. Ting WANG
Clinical and Regulatory Director
Mr. David Yanhua DU
General Manager of
Shenzhen Immuno Cure
Mr. Andy WONG
(Co-Founder)
Consultant
ABOUT
IMMUNO CURE
Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immune Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.
Learn More